Carla Concepcion-Crisol, PhD

Overview

Academic Appointments

  • Assistant Professor of Molecular Pharmacology and Therapeutics

Gender

  • Female

Credentials & Experience

Honors & Awards

  • Lung Cancer Research Foundation Minority Career Development Award, 2022
  • Koch Institute Frontier Research Award, 2019 – 2020
  • American Cancer Society Postdoctoral Fellowship, 2017 – 2021
  • Koch Institute Quinquennial Postdoctoral Fellowship, 2016
  • F31 Ruth L. Kirschstein National Research Service Award, 2013 – 2015

Research

Carla Concepcion, PhD is an Assistant Professor in the Department of Molecular Pharmacology & Therapeutics and a member of the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center. Dr. Concepcion received her BS in Molecular Biology & Biotechnology from the University of the Philippines in Manila. She obtained her PhD from Weill Cornell Graduate School of Medical Sciences of Cornell University where she studied microRNAs (miRNAs) in cancer and development in the lab of Dr. Andrea Ventura at Memorial Sloan Kettering Cancer Center. Dr. Concepcion did her postdoctoral training with Dr. Tyler Jacks at the Massachusetts Institute of Technology where she focused on the mechanisms through which alterations in SMARCA4, a core catalytic component of SWI/SNF chromatin remodeling complexes, transform the chromatin landscape and drive tumorigenesis in the lung. Dr. Concepcion began her independent research program at the Department of Molecular Pharmacology & Therapeutics at CUIMC in 2022. Her lab seeks to understand how altered chromatin states contribute to cell fates as tumors evolve with the goal of developing hypothesis-driven therapeutic strategies.

Selected Publications

  • Concepcion CP, Ma S, LaFave LM, Bhutkar A, Liu M, DeAngelo LP, Kim JY, Del Priore I, Schoenfeld AJ, Miller M, Kartha VK, Westcott PMK, Sánchez-Rivera FJ, Meli K, Gupta M, Bronson RT, Riely GJ, Rekhtman N, Rudin CM, Kim CF, Regev A, Buenrostro JD, Jacks T. Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. Cancer Discov. 2022 Feb;12(2):562-585. doi: 10.1158/2159-8290.CD-21-0248. Epub 2021 Sep 24. PubMed PMID: 34561242; PubMed Central PMCID: PMC8831463.
  • Gupta M, Concepcion CP, Fahey CG, Keshishian H, Bhutkar A, Brainson CF, Sanchez-Rivera FJ, Pessina P, Kim JY, Simoneau A, Paschini M, Beytagh MC, Stanclift CR, Schenone M, Mani DR, Li C, Oh A, Li F, Hu H, Karatza A, Bronson RT, Shaw AT, Hata AN, Wong KK, Zou L, Carr SA, Jacks T, Kim CF. BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer Res. 2020 Sep 15;80(18):3841-3854. doi: 10.1158/0008-5472.CAN-20-1744. Epub 2020 Jul 20. PubMed PMID: 32690724; PubMed Central PMCID: PMC7501156.
  • Li X*, Pritykin Y*, Concepcion CP*, Lu Y, La Rocca G, Zhang M, King B, Cook PJ, Au YW, Popow O, Paulo JA, Otis HG, Mastroleo C, Ogrodowski P, Schreiner R, Haigis KM, Betel D, Leslie CS, Ventura A. High-Resolution In Vivo Identification of miRNA Targets by Halo-Enhanced Ago2 Pull-Down. Mol Cell. 2020 Jul 2;79(1):167-179.e11. doi: 10.1016/j.molcel.2020.05.009. Epub 2020 Jun 3. PubMed PMID: 32497496; PubMed Central PMCID: PMC7446397. *equal contribution
  • Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014 Dec 18;516(7531):423-7. doi: 10.1038/nature13902. Epub 2014 Oct 22. PubMed PMID: 25337876; PubMed Central PMCID: PMC4270925.
  • Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet. 2012;8(7):e1002797. doi: 10.1371/journal.pgen.1002797. Epub 2012 Jul 26. PubMed PMID: 22844244; PubMed Central PMCID: PMC3406012